Catherine Tucker
About Catherine Tucker
Catherine Tucker is the Vice President of Business Development at BenevolentAI in London, United Kingdom, with over 25 years of experience in the pharmaceutical industry.
Company
Catherine Tucker is currently working at BenevolentAI as Vice President of Business Development. BenevolentAI is a leading company focused on the development and application of artificial intelligence (AI) and machine learning (ML) to accelerate scientific discovery and drug development. She is based in London, United Kingdom.
Title
Catherine Tucker holds the position of Vice President, Business Development at BenevolentAI. In this role, she is responsible for overseeing business growth through strategic partnerships, licensing, and the commercialization of innovative technologies.
Education and Expertise
Catherine Tucker has an extensive educational background that complements her professional expertise. She holds a Master of Business Administration (MBA) from The Open University Business School, where she studied Strategy, Financial Strategy, International Enterprise, and Performance & Evaluation. Additionally, she earned a Master of Science (MSc) in Clinical Pharmacology from the University of Aberdeen and a Bachelor of Science (BSc) (Hons) in Biochemistry from Aberystwyth University. Her combined education and over 25 years of experience equip her with a profound understanding of the pharmaceutical industry.
Background
Catherine Tucker has a robust background in business development, product development, and strategic consulting within the pharmaceutical industry. She has previously worked with prominent companies such as LUCID Consulting Ltd, Theramex, Allergan, Campbell Alliance, BTG (previously Protherics), IMS Health, UCB, and Elan Pharmaceuticals. Her roles have ranged from Director to Senior Business Development Executive, consistently focusing on growth through strategic partnerships and commercial assessments.
Achievements
Catherine Tucker's career is marked by her keen interest in pioneering sectors such as Autoimmune, Inflammation, Immunology, Microbiome, Immuno-Oncology, RNA, Cell and Gene Therapy, and AI/ML. She specializes in the development and commercialization of pharmaceutical products via licensing and strategic partnerships. Her track record includes driving growth and innovation in various companies over her extensive career spanning more than 25 years.